Last reviewed · How we verify

continuation of optimal medical therapy

Nantes University Hospital · Phase 1 active Small molecule Quality 3/100

continuation of optimal medical therapy is a Small molecule drug developed by Nantes University Hospital. It is currently in Phase 1 development. Also known as: Chait Trapdoor caecostomie catheter.

At a glance

Generic namecontinuation of optimal medical therapy
Also known asChait Trapdoor caecostomie catheter
SponsorNantes University Hospital
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about continuation of optimal medical therapy

What is continuation of optimal medical therapy?

continuation of optimal medical therapy is a Small molecule drug developed by Nantes University Hospital.

Who makes continuation of optimal medical therapy?

continuation of optimal medical therapy is developed by Nantes University Hospital (see full Nantes University Hospital pipeline at /company/nantes-university-hospital).

Is continuation of optimal medical therapy also known as anything else?

continuation of optimal medical therapy is also known as Chait Trapdoor caecostomie catheter.

What development phase is continuation of optimal medical therapy in?

continuation of optimal medical therapy is in Phase 1.

Related